Moreover, the 36-month beta value for ZVSA is 0.29. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZVSA is 2.34M and currently, short sellers hold a 0.85% of that float. On January 15, 2025, ZVSA’s average trading volume was 1.95M shares.
ZVSA) stock’s latest price update
ZyVersa Therapeutics Inc (NASDAQ: ZVSA)’s stock price has gone rise by 12.03 in comparison to its previous close of 1.33, however, the company has experienced a 19.20% increase in its stock price over the last five trading days. globenewswire.com reported 2024-12-18 that ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.
ZVSA’s Market Performance
ZyVersa Therapeutics Inc (ZVSA) has experienced a 19.20% rise in stock performance for the past week, with a 33.04% rise in the past month, and a -35.78% drop in the past quarter. The volatility ratio for the week is 21.05%, and the volatility levels for the past 30 days are at 14.27% for ZVSA. The simple moving average for the past 20 days is 25.88% for ZVSA’s stock, with a -54.98% simple moving average for the past 200 days.
ZVSA Trading at 19.87% from the 50-Day Moving Average
After a stumble in the market that brought ZVSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.04% of loss for the given period.
Volatility was left at 14.27%, however, over the last 30 days, the volatility rate increased by 21.05%, as shares surge +37.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.91% lower at present.
During the last 5 trading sessions, ZVSA rose by +19.20%, which changed the moving average for the period of 200-days by -80.84% in comparison to the 20-day moving average, which settled at $1.1836. In addition, ZyVersa Therapeutics Inc saw 40.57% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ZVSA
Current profitability levels for the company are sitting at:
- -617.08 for the present operating margin
- -0.0 for the gross margin
The net margin for ZyVersa Therapeutics Inc stands at -155140.06. The total capital return value is set at -1.22. Equity return is now at value -159.59, with -81.61 for asset returns.
Currently, EBITDA for the company is -107.74 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 231.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.03.
Conclusion
To wrap up, the performance of ZyVersa Therapeutics Inc (ZVSA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
